Cancer is not one disease. It is more than 200 distinct conditions — each defined by the cell type it originates from, the organ it affects, and the molecular changes that drive its growth. A breast cancer cell behaves differently from a leukemia cell. Prostate cancer responds to hormonal manipulation; brain tumors do not. The treatment for cervical cancer depends on entirely different mechanisms than the treatment for colorectal cancer.
This is why the single most important principle in oncology is matching treatment to diagnosis — not applying a generic protocol to every patient.
This guide provides a comprehensive overview of the most effective cancer treatment options by cancer type, explains each modern treatment modality in clinical depth, and outlines why India has become one of the world's most sought-after destinations for common cancer treatment options — delivering internationally benchmarked outcomes at a fraction of Western costs.
This is why many patients ask:
What is the best cancer treatment option for my cancer type? The answer depends on:
-
Type of cancer
-
Stage of cancer
-
Patient’s age and overall health
-
How fast the cancer is growing
This guide explains the best cancer treatment options by cancer type in simple, patient-friendly language.
Why Cancer Treatment Depends on Cancer Type
Cancer starts in different organs and cell types. Some cancers form solid tumors, while others affect blood and immune cells.
Doctors choose treatment based on:
- Where the cancer started
- Whether it has spread
- How aggressive it is
- How the body responds to therapy
There is no “one-size-fits-all” cancer treatment.
Best Cancer Treatment Options by Major Cancer Type
Breast Cancer
Breast cancer is the most commonly diagnosed cancer in women globally and has one of the broadest treatment arsenals of any malignancy. Treatment options by stage and subtype:
-
Surgery: Lumpectomy (breast-conserving) or mastectomy (total removal); sentinel lymph node biopsy to assess regional spread; reconstructive surgery can be performed simultaneously
-
Radiation therapy: Standard after lumpectomy to eliminate residual microscopic disease; also used post-mastectomy for high-risk cases
-
Chemotherapy: Recommended for hormone receptor-negative, HER2-positive, or triple-negative subtypes; can be given before surgery (neoadjuvant) to shrink tumors or after (adjuvant) to reduce recurrence risk
-
Hormone therapy: Tamoxifen (premenopausal), aromatase inhibitors (postmenopausal) — for hormone receptor-positive (ER+/PR+) tumors; typically continued for 5–10 years
-
Targeted therapy: Trastuzumab (Herceptin) and pertuzumab for HER2-positive tumors — dramatically improve survival in this subtype; CDK4/6 inhibitors (palbociclib, ribociclib) for hormone-positive advanced disease
-
Immunotherapy: Pembrolizumab approved for triple-negative breast cancer with high PD-L1 expression
India-specific note:Trastuzumab (Herceptin) biosimilars are available in India at significantly lower cost than the originator dru— making HER2-positive breast cancer treatment financially accessible for international patients.
Lung Cancer
Lung cancer remains the leading cause of cancer mortality globally. Treatment has been transformed in the past decade by targeted therapy and immunotherapy. Treatment options:
-
Surgery: Lobectomy, wedge resection, or pneumonectomy for Stage I–II non-small cell lung cancer (NSCLC); video-assisted thoracoscopic surgery (VATS) or robotic-assisted minimally invasive approaches are standard at India's leading centers
-
Chemotherapy: Platinum-based combination regimens (cisplatin/carboplatin with paclitaxel or pemetrexed) remain standard for non-targetable advanced NSCLC and for small cell lung cancer (SCLC)
-
Targeted therapy: Dramatically improves outcomes for patients with actionable mutations:
-
EGFR mutations: osimertinib (Tagrisso), gefitinib, erlotinib
-
ALK rearrangements: alectinib, crizotinib
-
ROS1, MET, KRAS G12C, BRAF, RET — each with specific targeted agents
-
-
Immunotherapy: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) based on PD-L1 expression — now first-line for many advanced NSCLC patients without targetable mutations
-
Radiation therapy: Stereotactic Body Radiation Therapy (SBRT) for early-stage patients who cannot tolerate surgery; consolidation radiation post-chemotherapy in limited-stage SCLC Molecular testing is mandatory before systemic treatment selection — NGS panel testing is available at India's leading oncology centers.
Colorectal (Colon and Rectal) Cancer
Treatment options:
-
Surgery: Colectomy, anterior resection, or abdominoperineal resection depending on tumor location; laparoscopic and robotic approaches reduce recovery time; liver metastasectomy when liver spread is limited and resectable
-
Chemotherapy: FOLFOX or FOLFIRI regimens are standard; capecitabine as oral alternative; neoadjuvant chemoradiation for locally advanced rectal cancer before surgery
-
Targeted therapy: Bevacizumab (anti-VEGF) and cetuximab or panitumumab (anti-EGFR, only in RAS wild-type tumors) added to chemotherapy backbones in advanced disease
-
Immunotherapy: Pembrolizumab approved as first-line for advanced colorectal cancer with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) — a highly effective subgroup
-
Radiation therapy: Primarily used in rectal cancer for local control before surgery (short-course or long-course chemoradiation)
Prostate Cancer
Treatment options depending on disease risk and extent: Active surveillance: For low-risk, slow-growing prostate cancer — regular PSA monitoring, biopsies, and MRI without immediate treatment; avoids overtreatment in favorable-prognosis disease
-
Surgery: Radical prostatectomy — robotic-assisted (Da Vinci) is the preferred approach, offering nerve-sparing potential to preserve urinary and sexual function; India's leading centers perform high volumes of robotic prostatectomies
-
Radiation therapy: External beam radiation (EBRT/IMRT/VMAT) or brachytherapy (radioactive seed implants); equally effective to surgery for localized disease in many patient groups
-
Hormone therapy (ADT): Androgen deprivation therapy; backbone of treatment for locally advanced and metastatic prostate cancer; combined with newer agents (enzalutamide, abiraterone, darolutamide) for metastatic disease
-
PSMA-targeted therapy: Lutetium-177 PSMA (Pluvicto) — a radioligand therapy for metastatic castration-resistant prostate cancer; increasingly available at India's leading nuclear medicine centers
Cervical Cancer
Treatment options:
-
Surgery: LEEP or cone biopsy for pre-invasive lesions; radical hysterectomy for Stage I–IIA invasive cervical cancer; lymph node dissection for staging
-
Chemoradiation: Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy — standard of care for locally advanced (Stage IIB–IVA) cervical cancer; highly effective when delivered at experienced radiation centers
-
Chemotherapy: For metastatic or recurrent disease — carboplatin/paclitaxel ± bevacizumab
-
Immunotherapy: Pembrolizumab approved for recurrent or metastatic cervical cancer with PD-L1 expression
Prevention note: HPV vaccination and cervical cancer screening programs (Pap smear, HPV DNA testing) prevent the majority of cervical cancer cases — a key message for international patients from regions where vaccination programs are less established.
Liver Cancer (Hepatocellular Carcinoma / HCC)
Treatment is strongly stage-dependent using the BCLC (Barcelona Clinic Liver Cancer) staging system — covered in detail in karetrip's dedicated liver cancer treatment guide. Treatment options summary:
-
Surgery (hepatectomy): Potentially curative for early-stage, single tumors with adequate remaining liver function
-
Liver transplant: Curative for patients within Milan Criteria — removes cancer and cures underlying liver disease simultaneously; India offers world-class living-donor liver transplant programs
-
Ablation (RFA, MWA): Minimally invasive tumor destruction for small tumors in patients who cannot undergo surgery
-
TACE (Transarterial Chemoembolization): Standard treatment for intermediate-stage HCC — chemotherapy delivered directly into the tumor's blood supply via catheter
-
Targeted therapy: Sorafenib, lenvatinib as first-line systemic agents; regorafenib, cabozantinib second-line
Immunotherapy: Atezolizumab + bevacizumab combination — now preferred first-line for advanced HCC in eligible patients
Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma)
Blood cancers involve the bone marrow, blood cells, and lymphatic system — and are treated fundamentally differently from solid tumors.
Leukemia:
-
Acute Leukemia (AML/ALL): Intensive induction chemotherapy aimed at achieving remission; followed by consolidation and, for high-risk patients, allogeneic bone marrow transplant (BMT)
-
CML (Chronic Myeloid Leukemia): Imatinib (Gleevec) and second-generation TKIs (dasatinib, nilotinib) — oral daily targeted therapy that has transformed CML from a terminal diagnosis to a manageable chronic condition
-
CLL: Watch-and-wait for asymptomatic disease; BTK inhibitors (ibrutinib, acalabrutinib), venetoclax + obinutuzumab for symptomatic disease
Lymphoma:
-
Hodgkin Lymphoma: ABVD chemotherapy ± radiation; highly curable in early stages (90%+ cure rate for Stage I–II); brentuximab vedotin and checkpoint inhibitors for relapsed/refractory disease
-
Non-Hodgkin Lymphoma: Treatment varies widely by subtype — R-CHOP for aggressive B-cell lymphomas; bendamustine + rituximab for indolent types; CAR-T cell therapy for relapsed diffuse large B-cell lymphoma
Multiple Myeloma:
Induction with bortezomib/lenalidomide/dexamethasone; followed by autologous stem cell transplant in eligible patients; maintenance with lenalidomide; newer agents (daratumumab, carfilzomib, pomalidomide) for relapsed/refractory myeloma
Brain Tumors
Brain tumor treatment is among the most technically complex in oncology — requiring neurosurgeons, radiation oncologists, and neuro-oncologists working in close collaboration. Treatment options:
-
Surgery: Maximal safe resection (removing as much tumor as possible without damaging critical brain function) — guided by intraoperative MRI, fluorescence (5-ALA), and awake craniotomy techniques at advanced centers
-
Radiation therapy: Standard post-operative radiation for high-grade gliomas (GBM); stereotactic radiosurgery (Gamma Knife, CyberKnife) for brain metastases and smaller benign tumors
-
Chemotherapy: Temozolomide (concurrent with radiation and then adjuvant) is standard for glioblastoma (GBM); CCNU/procarbazine for oligodendroglioma; methotrexate for primary CNS lymphoma
-
Targeted therapy: BRAF inhibitors for BRAF V600E-mutant gliomas; IDH inhibitors (vorasidenib) for IDH-mutant lower-grade gliomas — a recent advance changing the landscape for this subgroup
Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy and, in its most prevalent form (papillary thyroid cancer), has an excellent prognosis when treated appropriately. Treatment options:
-
Surgery: Total thyroidectomy or hemithyroidectomy depending on tumor size and risk category; central neck dissection if lymph node involvement suspected
-
Radioactive iodine (RAI) therapy: Post-surgical ablation of residual thyroid tissue and metastatic disease in differentiated thyroid cancers; administered as an oral dose
-
TSH suppression therapy: Lifelong levothyroxine to suppress TSH and reduce recurrence risk in intermediate-to-high-risk patients
-
Targeted therapy: Sorafenib, lenvatinib for radioiodine-refractory differentiated thyroid cancer; vandetanib, cabozantinib for medullary thyroid cancer
Ovarian Cancer
Treatment options:
-
Surgery: Comprehensive surgical staging and cytoreductive surgery (debulking) — removing as much cancer as possible including peritoneal deposits; the quality of initial surgery is one of the strongest prognostic factors
-
Chemotherapy: Carboplatin + paclitaxel is the standard first-line regimen; intraperitoneal delivery for selected patients; dose-dense weekly schedules in some protocols
-
PARP inhibitors: Olaparib, niraparib, rucaparib — maintenance therapy for BRCA-mutated or HRD-positive patients in remission; dramatically extend progression-free survival
-
Bevacizumab: Anti-angiogenic agent added to chemotherapy and continued as maintenance in advanced ovarian cancer
Cancer Treatment Costs in India vs USA and UK (By Treatment Type)
Cancer treatment cost in India typically ranges from ₹2 lakh to ₹25 lakh ($2,400–$30,000+) depending on cancer type, stage, and treatment plan — compared to $50,000–$500,000+ for equivalent treatment in the USA.
| Treatment Modality | India (USD) | USA (USD) | UK Private (USD) |
|---|---|---|---|
| Oncologist consultation | $30 – $80 | $200 – $500 | $150 – $350 |
| PET-CT scan | $300 – $600 | $3,000 – $6,000 | $1,500 – $3,000 |
| NGS molecular panel (biopsy) | $300 – $800 | $2,000 – $8,000 | $1,500 – $5,000 |
| Chemotherapy (per cycle) | $100 – $2,400 | $5,000 – $20,000 | $3,000 – $12,000 |
| Radiation therapy (full course) | $2,500 – $8,000 | $20,000 – $60,000 | $15,000 – $40,000 |
| Proton therapy (full course) | $15,000 – $35,000 | $30,000 – $120,000 | Limited availability |
| Immunotherapy (per cycle) | $960 – $3,000 | $15,000 – $25,000 | $8,000 – $15,000 |
| Targeted therapy (per month) | $960 – $3,000 | $10,000 – $15,000 | $6,000 – $12,000 |
| Cancer surgery (major) | $3,000 – $12,000 | $30,000 – $100,000 | $20,000 – $60,000 |
| Bone marrow transplant (BMT) | $14,000 – $35,000 | $250,000 – $500,000 | $100,000 – $200,000 |
Modern Cancer Treatments Explained Simply
- Chemotherapy
Uses drugs to kill cancer cells throughout the body.
- Radiation Therapy
Uses high-energy rays to destroy cancer cells in a specific area
- Targeted Therapy
Attacks specific changes in cancer cells with fewer side effects.
- Immunotherapy
Helps the immune system recognize and fight cancer.
- Surgery
Removes tumors when cancer is localized and operable.
- Proton Therapy
Proton therapy is one of the most advanced forms of radiation available — delivering a precise dose to the tumor with virtually zero exit dose to surrounding healthy tissue, making it particularly valuable for pediatric cancers (protecting developing organs), skull-base and spinal tumors near critical structures, and re-irradiation of previously treated areas.
India's Best Cancer Hospitals for International Patients
-
Tata Memorial Hospital, Mumbai, Tata Memorial is India's premier dedicated cancer center — a government institution offering the highest-quality oncology care at costs significantly lower than private hospitals. It is India's most published cancer research institution and attracts some of the country's most experienced oncologists. International patients can access care through its International Patient Centre, though waiting times for elective appointments can be longer than private centers.
-
Apollo Cancer Centres (Chennai, Delhi, Hyderabad, Bangalore) Apollo's dedicated cancer program includes South Asia's only proton therapy center (Chennai campus), comprehensive molecular diagnostics, robotic surgical oncology, and dedicated international patient pathways. Apollo is the most widely accessible premium cancer center network for international patients across India's major cities.
-
HCG (Healthcare Global Enterprises), Bangalore and Network HCG operates India's largest dedicated cancer hospital network — 27+ cancer centers across India — providing comprehensive oncology care from medical oncology through radiation, surgical oncology, bone marrow transplant, and nuclear medicine. Its exclusive cancer focus means every department, nurse, and piece of equipment is dedicated to oncology.
-
Medanta — The Medicity, Gurugram A comprehensive cancer care center within India's most advanced multi-specialty hospital. Medanta's oncology division covers the full treatment spectrum including robotic cancer surgery, advanced radiation (TrueBeam linac), immunotherapy infusion, and bone marrow transplant — under one roof in Delhi NCR.
-
Fortis Healthcare (Multiple Cities) A JCI-accredited hospital network with experienced oncology teams across Delhi, Mumbai, Bangalore, and Kolkata. Fortis is particularly well-regarded for its multidisciplinary cancer conferences and its experience managing patients from Bangladesh, the Middle East, and Africa.
-
Cancer Institute (WIA), Adyar, Chennai One of India's oldest and most respected dedicated cancer institutions — a charitable trust offering high-quality cancer care at significantly subsidized rates. Particularly appropriate for patients seeking affordable oncology care in South India.
How Cancer Treatment Is Decided: The Personalization Process
Before any treatment begins, diagnostic tests confirm cancer type, stage, and molecular profile. Imaging tests (X-ray, CT, MRI, PET-CT scan), biopsy, and blood tests confirm the cancer's condition. Either a single or a combination of treatment options is then advised based on type, stage, affected organ, severity, and overall patient health.
The process typically follows:
-
Diagnostic confirmation: Biopsy-based histopathological diagnosis
-
Staging investigations: CT chest/abdomen/pelvis, bone scan, PET-CT as indicated
-
Molecular profiling: NGS panel, immunohistochemistry, biomarker testing
-
MDT (Tumour Board) review: All specialists review together and reach consensus on treatment strategy
-
Treatment initiation: Surgery, systemic therapy, or radiation — or combination — in the sequence determined by the MDT
-
Response assessment: Mid-treatment imaging to confirm response and adjust plan if needed
-
Maintenance or surveillance: Ongoing follow-up, maintenance therapy where indicated, or post-treatment monitoring
How Doctors Decide the Best Treatment Plan
Doctors consider:
-
Cancer type and stage
-
Test results (biopsy, scans)
-
Patient’s overall health
-
Expected benefit vs side effects
Treatment is always personalized, not generic.
Not sure which treatment suits your cancer type? Ask Rua for expert guidance.** click here Chat with our WhatsApp agent RUA to understand your treatment options clearly.
Why Early Diagnosis Improves Treatment Success
Early-stage cancers:
-
Need less aggressive treatment
-
Have higher cure rates
-
Offer more options
Delaying care can limit treatment choices.
Why Many Patients Choose India for Cancer Treatment
India offers:
- Multispecialty cancer hospitals
- Experienced oncologists
- Advanced chemotherapy and radiation technology
- Affordable treatment packages
Patients from Bangladesh, Oman, Kenya, and Mauritius travel to India for high-quality cancer care.
How Karetrip Helps Cancer Patients
At karetrip.com we support international patients through every step of cancer care.
We help with:
- Choosing the right cancer hospital
- Connecting with top oncologists
- Second opinions
- Treatment planning
- Medical visas, travel, and accommodation
- End-to-end patient support
Confused about your cancer treatment options? Chat with our WhatsApp agent RUA for personalized guidanc
Medical Disclaimer:
This content is for general awareness only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.